Remdesivir and Flu Vaccinations not solutions to Covid Threat

WHO  Finds that  Gilead’s Remdesivir has ‘little or no effect’ on COVID-19 recovery or mortality

Nevertheless, Gilead expects to make $3.5 billion from Remdesivir this year 


Study Finds Positive association between COVID-19 deaths and influenza vaccination rates in elderly people worldwide 

Share this page

Follow Us